26 completed, 9 terminated, 5 recruiting, 4 unknown. 48 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 48 | Completed 26, Terminated 9, Recruiting 5, Unknown 4, Active not recruiting 2, Withdrawn 2 |
| Phase 2 | 8 | Completed 3, Terminated 2, Withdrawn 2, Recruiting 1 |
Follow Corticosteroids: new trials by email Literature Review of Corticosteroids trials Research Report on Corticosteroids
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant | Phase 2 / Phase 3 | Recruiting | Bambino Gesù Hospital and Research Institute | 1000 | 2026-01-07 | 2026-10-20 |
| Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases Bevacizumab, Dexamethasone - Radiation Necrosis, High Grade Glioma (III or IV) | Phase 3 | Recruiting | The Netherlands Cancer Institute | 408 | 2025-06-19 | 2026-07-13 |
| Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases Bevacizumab, Placebo, Prednisolone - Radionecrosis of Brain, Brain Metastases | Phase 3 | Recruiting | Institut Cancerologie de l'Ouest | 84 | 2025-04-29 | 2025-08-17 |
| A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease INCA034176, Placebo, Corticosteroids - Chronic Graft-versus-host-disease | Phase 3 | Recruiting | Incyte Corporation | 240 | 2025-01-21 | 2026-10-30 |
| Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants MDR-102, Immunosuppressive Agents - Kidney Transplant Rejection | Phase 2 / Phase 3 | Withdrawn | Medeor Therapeutics, Inc. | 2024-12-01 | 2024-06-07 | |
| Topical Sulfasalazine and Oral Lichen Planus sulfasalazine 500 MG, corticosteroids - Oral Lichen Planus, Topical Sulfasalazine | Phase 3 | Unknown | Cairo University | 46 | 2023-03-01 | 2024-08-01 |
| Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) Ianalumab, Placebo, Corticosteroids - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 226 | 2023-02-03 | 2026-11-09 |
| Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura Caplacizumab, Corticosteroids, anti-CD20 antibody - Thrombotic Thrombocytopenic Purpura | Phase 3 | Completed | Sanofi | 51 | 2022-11-21 | 2025-12-30 |
| A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications Belatacept, Tacrolimus, Cyclosporine A - Renal Allograft Recipients | Phase 3 | Recruiting | Bristol-Myers Squibb | 102 | 2021-07-21 | 2026-08-31 |
| Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD Pamrevlumab, Placebo, Corticosteroids - Duchenne Muscular Dystrophy | Phase 3 | Terminated | Kyntra Bio | 73 | 2021-03-03 | 2024-08-26 |
| Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children Dexamethasone Oral, Placebo - Urinary Tract Infections in Children, Dexamethasone | Phase 3 | Unknown | Hamad Medical Corporation | 120 | 2021-03-03 | 2023-07-25 |
| Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients Rebamipide, Nanoparticulated Rebamipide, Clobetasol Propionate - Rheumatoid Arthritis | Phase 3 | Unknown | Cairo University | 39 | 2020-12-01 | 2023-09-21 |
| Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) Pamrevlumab, Placebo, Corticosteroids - Duchenne Muscular Dystrophy | Phase 3 | Terminated | Kyntra Bio | 98 | 2020-08-10 | 2024-03-12 |
| Evaluation of Lycopene in the Treatment of Erosive Oral Lichen Planus Lycopene Softgel, 10 Mg, Prednisolone - Erosive Lichen Planus | Phase 2 / Phase 3 | Completed | Nourhan M.Aly | 20 | 2018-10-01 | 2020-12-03 |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Pacritinib, Physician's Choice medications - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Active not recruiting | Swedish Orphan Biovitrum | 407 | 2017-06-26 | 2026-04-30 |
| Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis). 5-ASA, Corticosteroids - Ulcerative Colitis | Phase 3 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 160 | 2016-06-13 | 2021-08-26 |
| Sodium Hyaluronate Injection and Corticosteroids in Trochanteric Bursitis: a Randomized Controlled Study. Corticosteroids, Hyaluronic acid - Osteoarthritis | Phase 3 | Unknown | Universitaire Ziekenhuizen KU Leuven | 30 | 2014-03-01 | 2014-03-26 |
| An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Tocilizumab, Prednisone, Tocilizumab Placebo - Giant Cell Arteritis | Phase 3 | Completed | Hoffmann-La Roche | 251 | 2013-07-22 | 2020-02-06 |
| 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients Everolimus, Tacrolimus, Cyclosporin A - Kidney Transplantation, Renal Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 612 | 2012-12-27 | 2017-05-01 |
| A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients tacrolimus, everolimus, Basiliximab - Liver Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 188 | 2012-12-01 | 2016-04-27 |
Showing 20 of 48. Sign in to see all of them.
Graft vs Host Disease (3) · Lupus Nephritis (3) · Autoimmune Diseases (2) · Brain Neoplasms (2) · Glomerulonephritis (2) · Lupus Erythematosus, Systemic (2) · Muscular Dystrophy, Duchenne (2) · Purpura, Thrombotic Thrombocytopenic (2) · Anemia (1) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Asthma (1) · Blood Loss, Surgical (1) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1)
Novartis Pharmaceuticals (7) · Hoffmann-La Roche (6) · Genentech, Inc. (3) · Astellas Pharma Inc (2) · Cairo University (2) · Kyntra Bio (2) · Novartis (2) · Bambino Gesù Hospital and Research Institute (1) · Bristol-Myers Squibb (1) · Carelon Research (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · EMD Serono (1) · Eli Lilly and Company (1) · Gaetano Ciancio (1) · Georgetown University (1)
United States (20) · France (19) · Italy (16) · Canada (15) · Germany (14) · Spain (14) · United Kingdom (14) · Belgium (13) · Australia (10) · Czechia (10) · Netherlands (10) · Argentina (8) · Austria (8) · Norway (8) · Poland (7)
Albert Assad, MD (1) · Aliaa A Bedeir, BDS (1) · Azza M Zaki, PhD (1) · Barbara Konkle, MD (1) · Christopher Hillyer, MD (1) · Cindy Leissinger, MD (1) · Craig Kessler, MD (1) · Darrell Triulzi, MD (1)
PMID 21536936, PMID 22257543, PMID 22325903, PMID 23230975, PMID 23252525, PMID 23422495, PMID 23471469, PMID 23714399, PMID 25504861, PMID 26151607, PMID 26338095, PMID 26888217, PMID 27220348, PMID 27723281, PMID 28745999, PMID 28817434, PMID 29045736, PMID 29507942, PMID 30582281, PMID 30786937, PMID 30824645, PMID 30835950, PMID 31530561, PMID 31760132, PMID 31790472, PMID 32912276, PMID 33217063, PMID 33223095, PMID 33232476, PMID 33465457, PMID 34049857, PMID 34303017, PMID 34718434, PMID 35947992, PMID 38279390, PMID 38676311, PMID 38993854, PMID 39082471, PMID 39382091, PMID 39739990, PMID 41348038
2009 (2), 2008 (1), 2015 (1), 2023 (1), 2025 (1), U01DC003209 (1), U01HL072268 (1)